A malar rash is a red or purplish discoloration that spreads symmetrically across both cheeks and the bridge of the nose, forming a shape that has earned it the nickname “butterfly rash.” It shows up in roughly half to two-thirds of people with systemic lupus erythematosus (SLE) and is one of the most recognizable signs of the disease. But lupus is not the only explanation for facial redness in that pattern, and mistaking a malar rash for something more common like rosacea can delay diagnosis by months or years.
What a Malar Rash Actually Looks Like
The classic malar rash drapes across the cheeks and over the nasal bridge in a continuous band. It can be flat or slightly raised, smooth or mildly scaly, and it ranges in color from faint pink to deep red or even violet-brown depending on skin tone. In some people the rash is fleeting, appearing after sun exposure and fading within hours; in others it lingers for weeks and leaves behind darker patches of pigmentation.
The single most important visual clue is where the rash does not go. A lupus-related malar rash characteristically spares the nasolabial folds, the creases that run from the sides of the nose down to the corners of the mouth. That sparing is a surprisingly reliable way to distinguish it from other causes of facial redness, and clinicians look for it during a physical exam.
The rash itself is usually not itchy. Some people describe mild warmth or tenderness, but intense itching or burning points away from lupus and toward other diagnoses. The rash also tends not to scar, which separates acute cutaneous lupus from the chronic discoid form that can leave permanent marks on the skin.
Why Lupus Is the Primary Cause
SLE is an autoimmune disease in which the immune system attacks the body’s own tissues. Skin is one of the most common targets, and the malar rash is seen in an estimated 46 to 65 percent of lupus patients over the course of their disease.1QJM: An International Journal of Medicine. Butterfly rash: hallmark of lupus The rash is considered highly specific for SLE, meaning that when it appears with its characteristic butterfly shape and nasolabial-fold sparing, it points strongly toward lupus rather than other conditions.
What drives the rash at the cellular level is a process called interface dermatitis: the immune system attacks the junction where the outer layer of skin meets the layer beneath it. Inflammatory cells gather at that boundary, disrupting normal skin architecture and producing visible redness and swelling. This pattern is distinct from what happens in most other facial rashes, which tend to center around blood vessels or hair follicles rather than that specific skin boundary.2PubMed Central. LC-OCT for Cutaneous Lupus Erythematosus: Characterization Across Disease Subtypes and Differentiation From Rosacea
The malar rash is also a signal that lupus may be doing damage beyond the skin. Many dermatologists consider a new-onset butterfly rash a reason to check for systemic involvement, including kidney inflammation, joint disease, and blood-count abnormalities. A rash alone does not confirm SLE, but it puts it on the diagnostic radar immediately.
How Sunlight Triggers and Worsens Flares
If you have lupus, ultraviolet (UV) light is probably your skin’s worst enemy. UV radiation is the dominant environmental trigger for cutaneous lupus lesions, capable of both initiating a new rash and worsening an existing one.3PubMed. Photosensitivity in lupus This photosensitivity is not just a mild inconvenience. In some people a few minutes of unprotected sun exposure is enough to provoke a full-blown flare.
The mechanism involves what happens to skin cells after UV damage. UV light causes accelerated cell death in the outermost layer of skin. Normally, the body quietly clears those dead cells. In lupus, the cleanup system fails: dead cells linger, break open, and spill their contents into surrounding tissue. Those cellular fragments are recognized by the immune system as foreign invaders, triggering a wave of inflammation that manifests as the rash.4PubMed Central. Pathophysiology of cutaneous lupus erythematosus 5PubMed. Photosensitivity, apoptosis, and cytokines in the pathogenesis of lupus erythematosus: a critical review
Both UVA and UVB radiation play a role, which is why standard window glass (which blocks UVB but lets UVA through) does not offer full protection. Fluorescent lighting can also be a problem for some lupus patients, since certain bulbs emit low levels of UV. Photosensitivity varies from person to person, but it is common enough that sun protection is considered a baseline part of lupus management rather than an optional add-on.
Conditions That Mimic a Malar Rash
Not every red face is lupus. Several conditions can produce facial redness in the cheek-and-nose area, and some are far more common than SLE.
- Rosacea: This is the most frequent source of confusion. Rosacea produces persistent facial redness, visible blood vessels, and sometimes small bumps, and it favors the central face in much the same area as a malar rash. The key differences are that rosacea usually does not spare the nasolabial folds, tends to involve tiny dilated blood vessels visible on the skin surface, and is centered around hair follicles and blood vessels rather than the deeper skin junction where lupus inflammation occurs.2PubMed Central. LC-OCT for Cutaneous Lupus Erythematosus: Characterization Across Disease Subtypes and Differentiation From Rosacea Even experienced dermatologists sometimes find the distinction challenging on visual inspection alone.6PubMed. Dermoscopy in the differential diagnosis between malar rash of systemic lupus erythematosus and erythematotelangiectatic rosacea: an observational study
- Seborrheic dermatitis: This produces flaky, greasy redness in areas with lots of oil glands, including the nose creases, eyebrows, and scalp. Unlike a lupus malar rash, it tends to fill the nasolabial folds rather than skip them.
- Contact dermatitis: An allergic or irritant reaction to something applied to the face, such as a new cosmetic or skincare product. The pattern usually maps to where the product was applied and is often itchy, which sets it apart from lupus.
- Dermatomyositis: This autoimmune condition can produce facial redness resembling a butterfly rash, but it typically does not spare the nasolabial folds and often includes a violet-colored rash over the eyelids (sometimes called a heliotrope rash) and scaly patches over the knuckles.1QJM: An International Journal of Medicine. Butterfly rash: hallmark of lupus
- Viral infections: Certain infections, particularly parvovirus B19 (fifth disease), can cause a “slapped cheek” appearance in both children and adults that looks superficially like a malar rash. The rash is usually symmetric and vivid red, but it fades within days and comes with flu-like symptoms rather than the joint pain and fatigue typical of lupus.
The overlap between these conditions is real enough that a visual exam alone is sometimes insufficient. When a clinician is unsure, blood tests for lupus-specific antibodies, a skin biopsy, or specialized imaging techniques can settle the question.
How a Malar Rash Is Diagnosed
Diagnosing a malar rash starts with a careful physical exam: noting the exact distribution, whether the nasolabial folds are spared, whether the rash is raised or flat, and whether there is scaling or scarring. But the exam is just the beginning.
Blood work typically includes tests for antinuclear antibodies (ANA), which are present in most lupus patients, and more specific antibodies like anti-double-stranded DNA and anti-Smith, which are much more targeted to SLE. A complete blood count, kidney function tests, and urinalysis round out the initial panel, because the rash may be the first visible sign of disease already affecting internal organs.
When the clinical picture is ambiguous, a skin biopsy can be decisive. In lupus, the biopsy shows the characteristic interface dermatitis pattern, with immune cells attacking the junction between skin layers. A related test called direct immunofluorescence looks for antibody deposits along that junction, which are common in lupus skin and absent in look-alike conditions like rosacea.7PubMed. Periorbital erythema and swelling as a presenting sign of lupus erythematosus in tertiary referral centers and literature review
One thing worth knowing: a malar rash by itself does not confirm SLE. Lupus diagnosis requires a combination of clinical findings and lab results. Someone with a butterfly rash but no other symptoms and negative antibody tests may be monitored over time rather than diagnosed on the spot. The rash is a strong hint, not a standalone verdict.
Treatment Options
Treatment for a lupus malar rash works on two levels: calming the rash directly and managing the underlying autoimmune process that produces it.
Topical Treatments
For mild flares confined to the skin, topical corticosteroid creams or ointments are the standard first step. They reduce redness and inflammation quickly, but prolonged use on the face comes with risks: thinning skin, visible blood vessels, and a rebound worsening when the cream is stopped. Because of those drawbacks, clinicians often limit steroid use on the face to short courses.
An alternative is topical tacrolimus, a non-steroidal immunosuppressant. In a small study, patients who applied tacrolimus ointment to one side of their face saw clear improvement in redness on the treated side compared with the untreated side after three weeks.8PubMed. Efficacy of topical tacrolimus for treating the malar rash of systemic lupus erythematosus Tacrolimus does not carry the same skin-thinning risk as corticosteroids, making it a more practical choice for longer-term facial use.
Systemic Medications
When the rash is persistent, widespread, or accompanied by other lupus symptoms, oral medications become the backbone of treatment. Hydroxychloroquine, originally an antimalarial drug, is the most widely used. A systematic review found that hydroxychloroquine at standard doses was effective for most cutaneous lupus patients, with response rates ranging from about 50 to 97 percent depending on the study.9PubMed. An update on the use of hydroxychloroquine in cutaneous lupus erythematosus: A systematic review A randomized controlled trial confirmed its efficacy and tolerability for cutaneous lupus specifically.10PubMed. Effects of Hydroxychloroquine in Patients With Cutaneous Lupus Erythematosus: A Multicenter, Double-Blind, Randomized, Parallel-Group Trial The drug takes several weeks to reach full effect, so patients should not expect overnight results.
Hydroxychloroquine does require periodic eye exams because, at high doses over many years, it can rarely cause damage to the retina. At standard doses, this risk is low, but regular monitoring is the accepted precaution.
Newer Therapies for Stubborn Cases
Some people with cutaneous lupus do not respond adequately to hydroxychloroquine, even when combined with topical treatments and other immunosuppressants. For these refractory cases, a newer biologic drug called anifrolumab has shown promising results. Anifrolumab works by blocking a receptor used by type 1 interferon, a signaling molecule that plays a central role in driving lupus skin inflammation.11PubMed. Anifrolumab for treatment of refractory cutaneous lupus erythematosus
In a study of seven patients who had tried a median of six prior treatments without adequate control, anifrolumab produced rapid and sustained improvement. Skin disease activity scores dropped significantly within the first month and continued improving, with a median reduction of about 60 percent by three months. Quality-of-life measures improved in parallel.12British Journal of Dermatology. Rapid efficacy of anifrolumab across multiple subtypes of recalcitrant cutaneous lupus erythematosus parallels changes in discrete subsets of blood transcriptomic and cellular biomarkers The evidence is still based on small studies, so anifrolumab is not a first-line option, but it represents a meaningful advance for people who have exhausted other treatments.
Sun Protection as Prevention
Given how strongly UV light drives lupus skin flares, sun protection is not just helpful, it is considered essential. A randomized, double-blind trial demonstrated that broad-spectrum sunscreen could prevent new skin lesions in photosensitive lupus patients across multiple subtypes of cutaneous lupus.13PubMed. Photoprotective effects of a broad-spectrum sunscreen in ultraviolet-induced cutaneous lupus erythematosus: a randomized, vehicle-controlled, double-blind study This is one of the clearest pieces of evidence in lupus management: sunscreen genuinely reduces flares, not just theoretically but in controlled testing.
Practical sun protection for lupus goes beyond a bottle of SPF 30. Broad-spectrum protection (covering both UVA and UVB) matters because UVA alone can provoke flares. Wide-brimmed hats, UV-protective clothing, and limiting time outdoors during peak sun hours all contribute. Some patients find that tinted sunscreens serve double duty by offering cosmetic coverage of residual redness while blocking UV.
Indoor environments are not automatically safe. As mentioned earlier, some fluorescent lights emit UV. People who work in offices with overhead fluorescent tubes may benefit from UV-filtering covers for those fixtures, though this is more of a concern for those with extreme photosensitivity.
Drug-Induced Malar Rashes
A butterfly rash does not always mean you have lupus. Certain medications can trigger a lupus-like syndrome, complete with a malar rash, autoimmune antibodies in the blood, and joint pain. The key difference is that drug-induced lupus resolves when the offending medication is stopped.
Classic culprits include hydralazine (a blood pressure drug), procainamide (a heart rhythm drug), and isoniazid (a tuberculosis medication). In one published case, a patient developed a textbook butterfly rash with nasolabial-fold sparing while receiving the chemotherapy drug paclitaxel. The rash appeared during treatment, autoimmune antibodies were detected in the blood, and both resolved after the drug was discontinued.14Case Reports in Oncology. Cremophor-Induced Lupus Erythematosus-Like Reaction with Taxol Administration: A Case Report and Review of the Literature
Drug-induced lupus is worth knowing about because it changes the management approach entirely. Instead of starting long-term immunosuppressive therapy, the solution is stopping or switching the medication. If you develop a new facial rash after starting a medication, telling your doctor about the timing is one of the most useful things you can do.
The Emotional Weight of a Facial Rash
A persistent rash on your face is not just a medical problem. It is a social one. The face is the first thing other people see, and visible skin conditions in that area consistently affect self-esteem, social confidence, and overall quality of life. Research on chronic facial dermatoses like rosacea shows that people with visible facial rashes report significantly lower quality of life and higher social anxiety compared with people without skin conditions.15PubMed Central. The Psychosocial Impact of Chronic Facial Dermatoses in Adults
Lupus patients face additional layers. The rash can flare unpredictably, making it hard to plan social events with confidence. Strict sun avoidance limits outdoor activities that friends and family take for granted. And because lupus is often invisible to others when the rash is absent, people with lupus sometimes face skepticism about the severity of their illness. Dermatology and rheumatology teams increasingly recognize that addressing the psychological impact of facial disease is part of comprehensive care, not a secondary concern. If a malar rash is affecting your mood, relationships, or daily functioning, it is worth raising with your doctor, because treatments that improve the rash often improve quality-of-life measures in parallel.
When to See a Doctor
Any new, persistent redness across both cheeks and the nose warrants a medical evaluation, especially if it appeared or worsened after sun exposure, if it spares the creases beside your nose, or if it comes alongside joint pain, unexplained fatigue, mouth sores, or hair loss. These accompanying symptoms raise the probability that the rash is connected to an autoimmune process rather than a benign skin condition.
Even if the rash seems minor, early evaluation matters. Lupus caught early and treated with hydroxychloroquine and sun protection tends to be far more manageable than lupus discovered only after it has already affected the kidneys or other organs. A dermatologist or rheumatologist can often make the distinction between lupus and its mimics within a single visit, using a combination of physical exam, blood work, and, if needed, a small skin biopsy. The rash is your body sending a signal. Paying attention to it early gives you the best chance of staying ahead of whatever is causing it.